Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

被引：75

作者：

Tabernero, Josep

Van Cutsem, Eric

Bang, Yung-Jue

Fuchs, Charles S.

Wyrwicz, Lucjan

Lee, Keun Wook

Kudaba, Iveta

Garrido, Marcelo

Chung, Hyun Cheol

Salguero, Hugo Raul Castro

Mansoor, Wasat

Braghiroli, Maria Ignez Freitas Melro

Goekkurt, Eray

Chao, Joseph

Wainberg, Zev A.

Kher, Uma

Shah, Sukrut

Kang, SoonMo Peter

Shitara, Kohei

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Inst Oncol, Barcelona, Spain

[3] Univ Hosp Gasthuisberg, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Yale Canc Ctr, New Haven, CT USA

[7] M Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[8] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[9] Riga East Univ Hosp, Riga, Latvia

[10] Pontificia Univ Catolica Chile, Santiago, Chile

[11] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[12] Hosp Enfermedad Comun Igss Zona 9, Guatemala City, Guatemala

[13] Christie NHS, Manchester, Lancs, England

[14] Univ Sao Paulo, Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[15] Univ Canc Ctr Hamburg, Hamburg, Germany

[16] City Hope Comprehens Canc Ctr, Duarte, CA USA

[17] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] Merck & Co Inc, Rahway, NJ 07065 USA

[20] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 18期

关键词：

D O I：

10.1200/JCO.2019.37.18_suppl.LBA4007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA4007

引用

页数：2

共 50 条

[1] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
Tabernero, J.
Van Cussem, E.
Bang, Y.
Fuchs, C.
Wyrwicz, L.
Lee, K.
Kudaba, I.
Garrido, M.
Chung, C.
Salguero, C. Castro
Mansoor, W.
Braghiroli, M.
Goekkurt, E.
Chao, J.
Wainberg, Z.
Kher, U.
Shah, S.
Karg, S.
Shitara, K.
ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
[2] Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
Chung, H. C.
Bang, Y-J.
Tabernero, J.
Van Cutsem, E.
Fuchs, C. S.
Wyrwicz, L.
Lee, K-W.
Kudaba, I.
Garrido, M.
Castro, H.
Mansoor, W.
Braghiroli, M. I.
Goekkurt, E.
Chao, J.
Wainberg, Z. A.
Kher, U.
Shah, S.
Shitara, K.
ANNALS OF ONCOLOGY, 2019, 30
[3] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Ohtsu, Atsushi
Kher, Uma
Lam, Baohoang
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[5] Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
Satake, Hironaga
Lee, Keun-Wook
Chung, Hyun Cheol
Lee, Jeeyun
Yamaguchi, Kensei
Chen, Jen-Shi
Yoshikawa, Takaki
Amagai, Kenji
Yeh, Kun-Huei
Goto, Masahiro
Chao, Yee
Lam, Ka-On
Han, Shi Rong
Shiratori, Shinichi
Shah, Sukrut
Shitara, Kohei
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 221 - 229
[6] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
Wainberg, Zev A.
Shitara, Kohei
Van Cutsem, Eric
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol Cheol
Lee, Jeeyun
Castro-Salguero, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Goekkurt, Eray
Satake, Hironaga
Chao, Joseph
Kher, Uma
Shah, Sukrut
Bhagia, Pooja
Tabernero, Josep
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[7] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Tabernero, Josep
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Janjigian, Yelena Yuriy
Bhagia, Pooja
Li, Kan
Adelberg, David
Qin, Shu Kui
FUTURE ONCOLOGY, 2021, 17 (22) : 2847 - 2855
[8] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[9] Pembrolizumab (pembro) versus standard of care chemotherapy (chemo) in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Satake, Hironaga
Lee, Keun Wook
Chung, Hyun Cheol
Lee, Jeeyuan
Yamaguchi, Kensei
Chen, Jen-Shi
Yoshikawa, Takaki
Amagai, Kenji
Yeh, Kun-Huei
Goto, Masahiro
Chao, Yee
Lam, Ka-On
Han, Shi Rong
Shiratori, Shinichi
Shah, Sukrut
Shitara, Kohei
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.
Rha, Sun Young
Lee, Jeeyun
Ryu, Min-Hee
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
Oh, Do-Youn
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 428 - 428

← 1 2 3 4 5 →